Arcus Biosciences (RCUS) Share-based Compensation (2017 - 2026)

Arcus Biosciences' Share-based Compensation history runs 10 years deep, the most recent figure standing at $19.0 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 18.75% year-over-year to $19.0 million in Q1 2026; TTM through Mar 2026 was $63.0 million, a 2000.0% increase from a year earlier, with the FY2025 full-year figure at $60.0 million, up 757.14% from the prior year.
• Share-based Compensation advanced to $19.0 million in Q1 2026 per RCUS's latest filing, from $15.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $20.0 million in Q1 2024 and bottomed at -$37.0 million in Q3 2023.
• The 5-year median for Share-based Compensation is $15.5 million (2022), against an average of $9.5 million.
• Across the five-year window, Share-based Compensation tumbled 327.55% in 2023 and jumped 1300.0% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $17.0 million in 2022, then plunged by 317.65% to -$37.0 million in 2023, then surged by 113.51% to $5.0 million in 2024, then soared by 200.0% to $15.0 million in 2025, then rose by 26.67% to $19.0 million in 2026.
• Per Business Quant, the three latest RCUS Share-based Compensation figures stand at $19.0 million (Q1 2026), $15.0 million (Q4 2025), and $14.0 million (Q3 2025).